Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Rare Kidney Diseases Market from 2024 to 2025?

The market size for rare kidney diseases has seen rapid expansion in the recent past. Predictions show an increase from $2.76 billion in 2024 to $3.06 billion in 2025, indicating a compound annual growth rate (CAGR) of 10.6%. The substantial growth during the historical period can be credited to better disease identification, the designation of orphan drugs, patient advocacy and awareness initiatives, as well as enhanced global research collaborations.

What Is the Projected Market Size of the Rare Kidney Diseases Market?

Anticipated to expand swiftly in the forthcoming years, the market size of rare kidney diseases is predicted to reach a mark of $4.49 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 10.1%. The upswing during the projected period can be credited to the advent of gene therapies, augmented investments in research pertaining to rare diseases, an increase in collaboration among stakeholders, along with universal drives for rare diseases. The chief trends in the forthcoming period are expected to comprise a focus on patient-oriented strategies, the application of real-world data and evidence, advancements in regulatory systems, the incorporation of telemedicine and remote surveillance, along with initiatives for global health.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11908&type=smp

Who are the Major Competitors in the Rare Kidney Diseases Market Outlook?

Major companies operating in the rare kidney diseases market include Merck & Co. Inc., Novartis AG, Sanofi S.A, AstraZeneca plc, Otsuka Pharmaceutical Co Ltd., Alexion Pharmaceuticals Inc., Horizon Therapeutics plc., Recordati S.p.A., Amicus Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics, FibroGen Inc., Aurinia Pharmaceuticals Inc., Calliditas Therapeutics AB, Apellis Pharmaceuticals Inc., Protalix Biotherapeutics Inc., ChemoCentryx Inc., Omeros Corporation, Celtaxsys Inc., Corbus Pharmaceuticals Holdings Inc., Chinook Therapeutics Inc., OxThera AB, Advicenne Pharma SA, Reata Pharmaceuticals Inc., Savara Inc.

What Is Fueling Growth in the Rare Kidney Diseases Market?

The advancement of the rare kidney disease market is anticipated to be driven by government initiatives and monetary support for kidney conditions. These initiatives and financing are forms of public financial assistance provided to selected parties with proposals or initiatives that enhance the standard of public services and stimulate the economy. Government support for kidney disorders is provided to bolster disease monitoring and enhance the life quality of those living with a variety of kidney diseases. This is accomplished through a comprehensive public health strategy that involves numerous public health organizations and national entities. For example, in July 2022, the United States House Committee on Appropriations, a committee working within the House of Representatives, introduced several investment schemes to improve kidney health. The program allotted $8.5 million to the Centers for Disease Control and Prevention’s (CDC) chronic kidney disease program, allowing it to enhance activities aimed at raising awareness, diagnosis, and treatment of kidney disease. Furthermore, a live donation investment of $1 million was contributed to the National Living Donor Assistance Center, resulting in a total of $8 million in continuous investment in innovation and research. As a consequence, government initiatives and support for kidney conditions are encouraging the expansion of the rare kidney disease market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11908&type=smp

Which Rare Kidney Diseases Market Segments Are Growing the Fastest?

The rare kidney diseases market covered in this report is segmented –

1) By Target Indication: IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy, Other Target Indications

2) By Type Of Molecule: Small Molecules, Biologics

3) By Route Of administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

Subsegments:

1) By IgA Nephropathy: Immunosuppressive Therapy, Supportive Care And Symptomatic Management

2) By Lupus Nephritis: Corticosteroids, Antimalarial Agents, Biologics

3) By Focal Segmental Glomerular Sclerosis (FSGS): Corticosteroids, Angiotensin Receptor Blockers (ARBs), Other Immunosuppressive Agents

4) By Membranous Nephropathy: Corticosteroids, Immunosuppressive Therapy, Monoclonal Antibodies

5) By C3 Glomerulopathy: Complement Inhibitors, Supportive Care, Immunosuppressive Therapies

6) By Other Target Indications: Alport Syndrome, Thin Basement Membrane Nephropathy, Other Rare Kidney Disorders

Which Industry Trends Are Shaping the Future of the Rare Kidney Diseases Market?

The trend of product innovation is garnering increasing attention in the rare kidney disease market. Key market leaders are focusing on devising innovative products to solidify their market standing. As an example, STADA Arzneimittel AG, a Germany-based firm engaged in generics, speciality pharma, and over-the-counter consumer health products, launched Kinpeygo (budesonide) in September 2022. This marks the first treatment for the rare kidney disease immunoglobulin A nephropathy (IgAN) authorized in the EU. These modified-release budesonide capsules remain the lone approved treatment for primary IgAN, a scarcely occurring, advancing autoimmune kidney disease that poses high unmet needs. It is important to note that approximately 25%-30% of patients ultimately suffer from terminal kidney deficiency, necessitating dialysis or a kidney transplant.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Which Countries Are Leading the Rare Kidney Diseases Market?

North America was the leading region in the rare kidney disease market in 2024. The regions covered in the rare kidney diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11908

This Report Delivers Insight On:

1. How big is the rare kidney diseases market, and how is it changing globally?

2. Who are the major companies in the rare kidney diseases market, and how are they performing?

3. What are the key opportunities and risks in the rare kidney diseases market right now?

4. Which products or customer segments are growing the most in the rare kidney diseases market?

5. What factors are helping or slowing down the growth of the rare kidney diseases market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model